oxi4503
Small moleculeexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00977210)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ca1p
- ca1p
- combretastatin a-1 bis(phosphate)
- combretastatin a-1 bis(phosphate)
- combretastatin a1 diphosphate
- combretastatin a1 diphosphate
- combretastatin a1 diphosphate
- oxi4503
- oxi4503
- oxi4503
- oxi4503
- oxi 4503
- oxi-4503
- oxi-4503
- oxi-4503
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02576301 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2015 | Mateon Therapeutics |
| NCT01085656 | Phase 1 | Feb 1, 2011 | The Leukemia and Lymphoma Society, University of Florida |
| NCT00960557 | Phase 1 | Jul 1, 2009 | Mateon Therapeutics, Mater Adult Hospital, Monash University, University of Adelaide, University of Western Australia |
| NCT00977210 | Phase 1 | Jul 1, 2005 | Cancer Research UK, Mateon Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mateon Therapeutics | For profit | 3 | 3 | 2 | 2005 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Mater Adult Hospital | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Adelaide | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Western Australia | Academic/Hospital | 1 | 0 | 1 | 2009 |
8 organizations
Page 1 / 1